# Rhenovia Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rhenovia-pharma

- Industry: Biotechnology
- Headquarters: Mulhouse, France
- Website: www.rhenovia.com
- Total disclosed funding: $0.4M
- Latest round: Series C (Jun 9, 2010)
- Investors on record: 2

## About

Rhenovia Pharma, based in Mulhouse, France, develops innovative health and wellness solutions focusing on therapeutic techniques and products aimed at enhancing well-being and addressing bodily dysfunctions.Rhenovia Pharma specializes in health and wellness solutions, focusing on fasciatherapy and organic silica supplements. Founded in 2007, the company is headquartered in Mulhouse, France. In May 2013, Rhenovia raised EUR 42,971.4 in venture funding from individual investors, which contributed to its total amount raised of EUR 0.043 mn, leading to a current company valuation of EUR 2.518 mn.Rhenovia specializes in innovative health and wellness solutions that encompass a range of therapeutic techniques and complementary products. Central to their offerings is fasciatherapy, a gentle method aimed at targeting the fascia, the connective tissues surrounding muscles and organs. This therapy is designed to alleviate various bodily dysfunctions and enhance overall mental well-being. Additionally, Rhenovia provides organic silica supplements known for their numerous health benefits, particularly for joint health, skin, hair, and nails. The company’s offerings also extend to holistic practices such as couple therapy and support for various health concerns including hair loss and cosmetic procedures, like permanent hair removal. Rhenovia serves a diverse clientele across multiple geographical markets, focusing on regions where wellness and alternative health practices are in demand, including urban centers in Europe and North America.Rhenovia generates revenue through a combination of direct-to-consumer sales and professional partnerships, particularly within the health and wellness sectors. The company’s revenue model typically involves clients purchasing individual sessions of fasciatherapy or subscribing to a series of treatments, allowing for a structured approach to wellness. Additionally, their organic silica products are sold through both retail outlets and online platforms, catering to health-conscious consumers. The pricing structure is tailored to accommodate various client needs, with options available for both single sessions and bundled service packages. Rhenovia's trademarked products and services are positioned to appeal to both individual consumers and healthcare practitioners, enhancing their market reach and revenue potential.Rhenovia Pharma's future growth strategy includes launching new products designed to enhance their therapeutic offerings, although specific release dates are not provided. The company aims to expand its market presence into new geographic regions, specifically targeting urban centers in Europe and North America by 2025. The recent funding raised in May 2013 will be utilized to support these initiatives, helping to bolster product development and market expansion efforts.

## Funding rounds

- Series C, Jun 9, 2010, $0.4M — SODIV, Alsace Business Angels

## Investors

- SODIV — Series C
- Alsace Business Angels (https://capitalatlas.ai/funds/alsace-business-angels) — Series C